CU23914B1 - DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA - Google Patents

DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA

Info

Publication number
CU23914B1
CU23914B1 CU2010000262A CU20100262A CU23914B1 CU 23914 B1 CU23914 B1 CU 23914B1 CU 2010000262 A CU2010000262 A CU 2010000262A CU 20100262 A CU20100262 A CU 20100262A CU 23914 B1 CU23914 B1 CU 23914B1
Authority
CU
Cuba
Prior art keywords
derivatives
coa
estearoil
piridin
dihidro
Prior art date
Application number
CU2010000262A
Other languages
English (en)
Other versions
CU20100262A7 (es
Inventor
Natalie Dales
Zaihui Zhang
Jianmin Fu
Duanjie Hou
Shaoyi Sun
Vishnumurthy Kodumuru
Natalia Pokrovskaia
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of CU20100262A7 publication Critical patent/CU20100262A7/es
Publication of CU23914B1 publication Critical patent/CU23914B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona derivados heterocíclicos que modulan la actividad de la estearoil-CoA-desaturasa (SCD). También se abarcan métodos para utilizar estos derivados con el fin de modular la actividad de la estearoil-CoA-desaturasa (SCD), y composiciones farmacéuticas que comprenden tales derivados.
CU2010000262A 2008-06-27 2010-12-27 DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA CU23914B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7644308P 2008-06-27 2008-06-27
PCT/EP2009/057998 WO2009156484A2 (en) 2008-06-27 2009-06-25 Organic compounds

Publications (2)

Publication Number Publication Date
CU20100262A7 CU20100262A7 (es) 2011-11-15
CU23914B1 true CU23914B1 (es) 2013-07-31

Family

ID=41445023

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000262A CU23914B1 (es) 2008-06-27 2010-12-27 DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA

Country Status (25)

Country Link
US (2) US9187426B2 (es)
EP (1) EP2307379A2 (es)
JP (1) JP5529124B2 (es)
KR (2) KR20110022089A (es)
CN (1) CN102119152B (es)
AU (1) AU2009264242A1 (es)
BR (1) BRPI0913966A2 (es)
CA (1) CA2729327C (es)
CL (1) CL2010001526A1 (es)
CO (1) CO6341563A2 (es)
CR (1) CR11862A (es)
CU (1) CU23914B1 (es)
EA (1) EA201100049A1 (es)
EC (1) ECSP11010787A (es)
GT (1) GT201000376A (es)
HN (1) HN2010002774A (es)
IL (1) IL210118A0 (es)
MA (1) MA32508B1 (es)
MX (1) MX2010014572A (es)
NZ (1) NZ589962A (es)
PE (1) PE20110136A1 (es)
SG (1) SG192439A1 (es)
SV (1) SV2010003777A (es)
WO (1) WO2009156484A2 (es)
ZA (1) ZA201008951B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007351498B2 (en) 2006-08-15 2012-04-05 Xenon Pharmaceuticals Inc. Organic compounds
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
CN102007123B (zh) 2008-02-20 2014-04-30 诺华股份有限公司 硬脂酰基-CoA去饱和酶的杂环抑制剂
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US8598209B2 (en) * 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
BRPI1015568B8 (pt) 2009-06-26 2021-05-25 Novartis Ag derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
CA2813708C (en) * 2010-10-18 2019-09-17 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
DK2648516T3 (da) 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
ES2712803T3 (es) 2011-02-28 2019-05-14 Biomarin Pharm Inc Inhibidores de histona desacetilasa
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CA2834224A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17.alpha.-hydroxylase/c17,20-lyase inhibitors
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
KR101979042B1 (ko) 2011-08-04 2019-05-15 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
JP2015503505A (ja) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
PT2820009T (pt) 2012-03-01 2018-04-12 Array Biopharma Inc Inibidores de serina/treonina quinases
EP2858501A4 (en) * 2012-05-22 2015-12-09 Merck Sharp & Dohme TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
NZ711585A (en) 2013-03-15 2020-05-29 Biomarin Pharm Inc Hdac inhibitors
KR102313515B1 (ko) 2013-06-07 2021-10-14 어클라리스 쎄라퓨틱스, 인코포레이티드 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
PL3177612T3 (pl) 2014-08-04 2022-08-08 Nuevolution A/S Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
SMT202100702T1 (it) 2015-07-06 2022-01-10 Alkermes Inc Inibitori etero-alo dell'istone deacetilasi
WO2017043341A1 (ja) * 2015-09-08 2017-03-16 住友化学株式会社 トリアゾール化合物
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
TWI769266B (zh) * 2017-06-20 2022-07-01 日商拉夸里亞創藥股份有限公司 作為Nav1.7及Nav1.8阻斷劑之醯胺衍生物
DK3664802T3 (en) 2017-08-07 2022-05-30 Alkermes Inc Bicyclic inhibitors of histone deacetylase
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
CN114222574B (zh) * 2019-04-30 2024-12-17 瓦洛健康股份有限公司 抑制usp36
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
NZ786543A (en) 2019-12-20 2026-01-30 Nuevolution As Compounds active towards nuclear receptors
MX2022011755A (es) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos.
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CN120987645B (zh) * 2025-10-24 2026-01-23 河北国亮新材料股份有限公司 一种洁净钢用中间包复合涂抹料及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6133172A (ja) * 1984-07-24 1986-02-17 Kotobuki Seiyaku Kk １，３−置換−２−イミダゾリジノン誘導体，胃腸運動亢進剤及びその製造方法
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
JPH0249725A (ja) * 1988-05-13 1990-02-20 Tanabe Seiyaku Co Ltd 脳代謝賦活剤
JP3916092B2 (ja) 1993-09-17 2007-05-16 杏林製薬株式会社 イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
US5607932A (en) * 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
MXPA01009805A (es) 1999-03-29 2004-07-30 Univ Ulster Peptido.
DE60039111D1 (de) 1999-09-28 2008-07-17 Bayer Corp Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
US6987001B2 (en) 2000-02-24 2006-01-17 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
BR0111280A (pt) * 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
EP1322767B1 (en) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Methods and compositions employing a stearoyl-coa desaturase-hscd5
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
EP1542667B1 (en) * 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
JP2004107323A (ja) * 2002-07-26 2004-04-08 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法
KR20050026535A (ko) * 2002-07-31 2005-03-15 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3 억제성 안트라닐아미도피리딘
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN101090724A (zh) 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2006343359A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors

Also Published As

Publication number Publication date
ZA201008951B (en) 2012-02-29
ECSP11010787A (es) 2011-02-28
CA2729327C (en) 2016-10-11
SG192439A1 (en) 2013-08-30
KR20130084328A (ko) 2013-07-24
WO2009156484A2 (en) 2009-12-30
HN2010002774A (es) 2013-01-28
US20110105530A1 (en) 2011-05-05
CL2010001526A1 (es) 2011-07-01
CR11862A (es) 2011-02-16
CO6341563A2 (es) 2011-11-21
CN102119152B (zh) 2014-07-02
CU20100262A7 (es) 2011-11-15
WO2009156484A3 (en) 2010-05-14
JP5529124B2 (ja) 2014-06-25
NZ589962A (en) 2012-12-21
AU2009264242A1 (en) 2009-12-30
CA2729327A1 (en) 2009-12-30
PE20110136A1 (es) 2011-03-17
IL210118A0 (en) 2011-02-28
KR20110022089A (ko) 2011-03-04
SV2010003777A (es) 2011-07-05
CN102119152A (zh) 2011-07-06
MA32508B1 (fr) 2011-07-03
EP2307379A2 (en) 2011-04-13
JP2011525896A (ja) 2011-09-29
US9187426B2 (en) 2015-11-17
MX2010014572A (es) 2011-03-24
US20160289191A1 (en) 2016-10-06
EA201100049A1 (ru) 2011-08-30
BRPI0913966A2 (pt) 2015-11-17
GT201000376A (es) 2013-09-09

Similar Documents

Publication Publication Date Title
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
CO6290655A2 (es) Inhibidors heterociclicos de estearoil-coa-desaturasa
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
MX2009003080A (es) Compuestos organicos heterociclicos.
CL2009000245A1 (es) Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros.
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MX392150B (es) Moduladores de receptores canabinoides.
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
GT201100039A (es) Agentes antifúngicos
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата
TN2010000598A1 (en) Organic compounds
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)